By Fineline Cube 
Shanghai-listed biopharmaceutical company Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) has announced plans to invest RMB787 million (USD 108 million) in the construction of a dual-functional R&D and GMP manufacturing facility. The project will be located within Beijing’s Yizhuang New Town BioPark, a leading biotech cluster in the capital.
Development Plan
The 3-year development plan for the new facility includes the establishment of a core R&D hub, a clinical development center, a commercial manufacturing base, a quality assurance complex, and commercial operations infrastructure. This comprehensive approach aims to integrate research, development, and production under one roof, enhancing efficiency and innovation in the biopharmaceutical sector.-Fineline Info & Tech